Indeed, we identified the frequent EGFR alterations in GBM as predictors of TAT-Cx43266–283 response and part of its mechanism of action, we showed effects in TMZ- and erlotinib-resistant GSCs and we revealed that TAT-Cx43266–283 targets NSCs with GBM-driver mutations, including EGFR alterations, in an immunocompetent GBM model in vivo. The gene discussed is EGFR; the disease is glioblastoma.